Decera Clinical Education Neuroscience Podcast

The introduction of muscarinic receptor agonism offers a new approach to schizophrenia treatment beyond traditional dopamine D2 receptor blockade. Listen in while Rebecca DePalma, DMSc, PA-C, explores the rationale behind targeting this new mechanism and emerging evidence for muscarinic therapies, with a focus on xanomeline/trospium. Through a discussion of efficacy, safety, and practical prescribing considerations, find out how these advances may apply to your practice and improve patient-centered care.Presenter:Rebecca DePalma, DMSc, PA-C​Psychiatric Physician Associate​Doctorate of Medical Science​Adjunct Clinical Faculty, Pacific University​Co-Author of First Line Guide: Psychiatric and ​Behavioral Medicine​Seattle, WashingtonLink to full program:https://bit.ly/4gvLZYmGet access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Effective acute pain management requires balancing adequate pain relief with the risks and limitations of available analgesics. Listen in as Mitchell P. Engle, MD, PhD; Kathy Kates, FNP-BC; Michael Sprintz, DO, DFASAM; and Amanda Zimmerman, PA-C, explore emerging non-opioid treatment options, including selective NaV1.8 inhibition with suzetrigine, and the role of multimodal analgesia in acute pain management to find out how to expand your pain tool kit and improve patient-centered care.Presenters:Mitchell P. Engle, MD, PhDScientific and Medical ConsultantPartner, Institute of Precision Pain Medicine​Corpus Christi, Texas​Kathy Kates, FNP-BCCEOPelvic Health Support​Brookline, Massachusetts​Michael Sprintz, DO, DFASAMMedical Director, Substance Abuse and Mental Health IOP Programs​The Lovett Behavioral Health Group​Houston, Texas​Amanda Zimmerman, PA-CWest Forsyth Pain Management​Winston-Salem, North Carolina​Link to full program:https://bit.ly/4swPrGLGet access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Emerging therapies are reshaping schizophrenia care by introducing novel mechanisms that extend beyond traditional dopamine receptor blockade. Listen in to learn from Dr Leslie Citrome about evolving concepts in schizophrenia neurobiology; the clinical evidence supporting emerging therapeutic approaches with a focus on muscarinic-targeted therapies; and practical strategies for translating these advances into patient care, including treatment selection, safety, and tolerability considerations. Presenter:Leslie Citrome, MD, MPH Clinical Professor, Psychiatry and Behavioral Sciences New York Medical College Valhalla, New York Adjunct Professor, Psychiatry and Behavioral Sciences Northwestern Feinberg School of Medicine Chicago, Illinois Link to full program:https://bit.ly/4gvLZYm Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novel C5 inhibitors are reshaping individualized care for generalized myasthenia gravis. Listen in to learn from Drs Muppidi, Narayanaswami, Kaminski, and Paul about persistent needs in gMG care, clinical differences among C5 inhibitors, and practical considerations for matching treatment decisions to patient goals, access, safety, and long-term adherence. Presenters: Srikanth Muppidi, MD Clinical Professor Department of Neurology and Neurological Sciences Stanford University Stanford, California Pushpa Narayanaswami, MD, FAAN Professor of Clinical Neurology Harvard Medical School Vice Chair, Clinical Operations Department of Neurology Beth Israel Deaconess Medical Center Boston, Massachusetts Henry J. Kaminski, MD Jeffrey Lieberman Professor of Neurosciences Professor of Neurology, Pharmacology & Physiology George Washington University Principal Investigator, MGNet Rare Disease Clinical Research Consortium Washington, DC Pritikanta Paul, MD Assistant Professor of Neurology University of California, San Francisco Co-Director, MG Clinic San Francisco, California Link to full program: https://bit.ly/4aXq3Ce Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiple sclerosis care is evolving fast, from what current AAN guidance emphasizes to what’s emerging in the treatment pipeline. In this episode, Patricia K. Coyle, MD, FAAN, FANA, reviews practical, patient-centered principles for MS management, including shared decision-making, realistic expectations, adherence, monitoring, and optimizing comorbidities and lifestyle factors. She also explains when to reassess and potentially switch therapy based on relapses, disability progression, and MRI activity, and highlights pipeline advances such as CNS-penetrant BTK inhibitors and other investigational approaches. Presenters:Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/4dhvLAL Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Wondering what is coming next in MS care beyond today’s disease-modifying therapies? This episode spotlights CNS-penetrant oral BTK inhibitors and the fast-moving pipeline targeting neuroinflammation, immune reset, and future CNS repair, then brings it to life with a real patient case that tests treatment selection and the decision to switch therapy. Led by Patricia K. Coyle, MD, FAAN, FANA, it is a practical listen for healthcare professionals who want a clear sense of where MS treatment is heading and why it matters now. Presenters: Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/4sau7px Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiple sclerosis (MS) is increasingly understood as a spectrum in which relapsing activity and progression can overlap, creating a need for smart, individualized use of disease-modifying therapies. Listen in to learn from Patricia K. Coyle, MD, FAAN, FANA, for a practical review of today’s MS DMT options, with a focus on high-efficacy monoclonal antibodies such as anti-CD20 therapies, how healthcare professionals think about progression concepts like PIRA and RAW, and what emerging trial designs like OCTOPUS may mean for improving treatment options in progressive MS. Presenter: Patricia K. Coyle, MD, FAAN, FANA Distinguished Professor of Neurology Vice Chair for Academic Affairs Department of Neurology Stony Brook Renaissance School of Medicine Director, MS Comprehensive Care Center Stony Brook, New York Link to full program:https://bit.ly/3PdRks4 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. For additional activities in this program including a ClinicalThought commentary, a CME/CE/CPE certified on-demand webcast and a downloadable slideset, go to: https://bit.ly/4qjcYcjFaculty:Jonathan M. Meyer, MD, DLFAPAVoluntary Clinical Professor of PsychiatryUniversity of California, San DiegoSenior Academic AdviserCalifornia Department of State HospitalsSan Diego, CaliforniaGet access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.Topics covered include:Evoke and evoke+ phase III trials of semaglutideSubcutaneous lecanemab as initiation and maintenance treatmentBlood-based biomarker assaysTrontinemab and other brain shuttlesTau targeting therapies in developmentPreventive impact of BCG and herpes zoster vaccinationThis podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk. Faculty:Anton P. Porsteinsson, MD William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and MedicineDirector, Alzheimer's Disease Care, Research and Education Program (AD-CARE)University of Rochester School of Medicine and DentistryRochester, New YorkVijay K. Ramanan, MD, PhDConsultant and Associate ProfessorDirector, Alzheimer’s Disease Treatment ClinicDepartment of NeurologyMayo ClinicRochester, Minnesota Link to obtain CME/CE credit: https://bit.ly/4999otE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for younger kids and their implementation by the patient care team.Faculty:Danielle Becker, MD, MS, FAES Division Director of EpilepsyAssociate Professor of NeurologyThe Ohio State University Wexner Medical CenterColumbus, Ohio Sarah Weatherspoon, MDAssociate Chief of Child NeurologyTuberous Sclerosis Center of Excellence, Neurology Co-DirectorLe Bonheur Children's HospitalUniversity of Tennessee Health Science CenterMemphis, TennesseeResources mentioned in this episode:Epilepsy Foundation Seizure Action Plan ToolkitCDC Managing Epilepsy Well (MEW) NetworkLink to Brain Health Hub with additional educational activities: https://bit.ly/3Y12Isx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.